Literature DB >> 7758165

Intraischemic preconditioning. Increased tolerance to sustained low-flow ischemia by a brief episode of no-flow ischemia without intermittent reperfusion.

R Schulz1, H Post, S Sakka, D R Wallbridge, G Heusch.   

Abstract

Ischemic preconditioning (IP) and myocardial hibernation (MH) are both adaptive phenomena during acute myocardial ischemia, characterized by preserved myocardial viability and attenuated alterations of energy metabolism. Recent data from isolated buffer-perfused rabbit hearts pointed to a further link between IP and MH, in that an initial stimulus of no-flow ischemia was required to permit the development of MH during subsequent sustained low-flow ischemia. In the present study, we therefore investigated in the in situ pig heart whether a brief episode of no-flow ischemia enhances the myocardial tolerance to subsequent sustained low-flow ischemia. By blocking ATP-dependent potassium channels, we attempted to further determine whether such increased tolerance to ischemia is related to IP or MH, since blockade of ATP-dependent potassium channels abolishes the cardioprotection achieved by IP but not by MH. In 8 enflurane-anesthetized pigs serving as controls (group 1), the inflow into the cannulated left anterior descending coronary artery was reduced to achieve a 90% reduction in the anterior myocardial work index (sonomicrometry) for 90 minutes. In 15 pigs (group 2), a 10-minute no-flow ischemic episode preceded 80 minutes of sustained ischemia at a blood flow reduction identical to that in pigs of group 1. In 8 additional pigs (group 3), glibenclamide was administered before the 10-minute no-flow ischemic episode. In all pigs after 120 minutes of reperfusion, infarct size (IS, percentage of area at risk) was determined by triphenyltetrazolium chloride staining. In group 2, IS was reduced (6.8 +/- 6.0% [mean +/- SD], P < .05) when compared with groups 1 (13.2 +/- 9.8%) and 3 (16.7 +/- 8.3%).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7758165     DOI: 10.1161/01.res.76.6.942

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  9 in total

Review 1.  Therapeutic potential of ischaemic preconditioning.

Authors:  R J Edwards; A T Saurin; R D Rakhit; M S Marber
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

2.  Activation of ATP-dependent potassium channels is a trigger but not a mediator of ischaemic preconditioning in pigs.

Authors:  Rainer Schulz; Petra Gres; Gerd Heusch
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

Review 3.  Three questions about preconditioning.

Authors:  M Connaughton; D J Hearse
Journal:  Basic Res Cardiol       Date:  1996 Jan-Feb       Impact factor: 17.165

Review 4.  Preconditioning--a reappraisal of protection.

Authors:  L M King; L H Opie
Journal:  Basic Res Cardiol       Date:  1996 Jan-Feb       Impact factor: 17.165

Review 5.  Ischemic preconditioning and myocardial hibernation: is there a common mechanism?

Authors:  R Schulz; G Heusch
Journal:  Basic Res Cardiol       Date:  1996 Jan-Feb       Impact factor: 17.165

Review 6.  Cardioprotection by organs in stress or distress.

Authors:  P D Verdouw; B C Gho; D J Duncker
Journal:  Basic Res Cardiol       Date:  1996 Jan-Feb       Impact factor: 17.165

7.  Potentially neuroprotective gene modulation in an in vitro model of mild traumatic brain injury.

Authors:  Valentina Di Pietro; Angela M Amorini; Barbara Tavazzi; David A Hovda; Stefano Signoretti; Christopher C Giza; Giacomo Lazzarino; Roberto Vagnozzi; Giuseppe Lazzarino; Antonio Belli
Journal:  Mol Cell Biochem       Date:  2012-12-15       Impact factor: 3.396

Review 8.  Features of short-term myocardial hibernation.

Authors:  G Heusch; R Schulz
Journal:  Mol Cell Biochem       Date:  1998-09       Impact factor: 3.396

9.  Determinants of delayed preconditioning against myocardial stunning in chronically-instrumented pigs.

Authors:  James A Fallavollita
Journal:  J Cardiovasc Transl Res       Date:  2009-03       Impact factor: 4.132

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.